Absorption. Any National Wage and/or Living Wage adjustment occurring during the term of this Agreement will not be applied to rates of pay applying under this Agreement.
Absorption. The provisions of this clause are in substitution for and not cumulative upon the relevant provisions of the Metal, Engineering and Associated Industries Award (1998).
Absorption. 42.1 An Employee who is, prior to the commencement of this Agreement, being paid at a rate of pay in excess of the rates prescribed in Schedule C of this Agreement for their respective classification, shall not have their rate of pay increased in accordance with clause 40 of this Agreement, unless their rate of pay falls below that provided in Schedule C. In such circumstances, the Employee shall be paid in accordance with the rate of pay prescribed in Schedule C for their respective classification.
Absorption. In keeping with the principles of equity, employees who are paid above the pay rates specified in schedule B may not receive an across the board fixed pay increase until their pay falls within the maximum of the pay range relevant to their position.
Absorption. On successful completion of the Training Period, of which the Company shall be the sole judge, the Company will consider offering you employment in a suitable grade in the Company and will be based at any of our proposed SEZ sites or any other location across India. Your annual CTC including all benefits will be as per the details mentioned in ‘Annexure-2’.
Absorption. (a) For each of its assigned areas of responsibility, RDOEC will maintain, on a monthly basis, a rolling 12-month product support absorption percentage at a level greater than the level corresponding to the 50th percentile of all of JDIEC's U.S. dealers. Product support absorption percentage will be determined based upon the criteria and methodology then in use by JDIEC and evaluated monthly as information becomes available. The areas of responsibility assigned to RDOEC will be excluded from the calculations for the purpose of determining the 50th percentile of JDIEC's U.S. dealers.
(b) JDIEC will have the right to terminate RDOEC's dealer appointments for a given area of responsibility upon the third instance (or any subsequent instance) in which RDOEC fails, in that area of responsibility, to satisfy the performance requirement set forth in section 4.a(3)(a) above, whether the instances occur in consecutive months or otherwise. Such termination will require one year advance written notice. JDIEC will have no obligation to rescind a notice of termination given under this section 4.a(3)(b) even if RDOEC satisfies the performance requirement set forth in section 4.a(3)(a) above in the area of responsibility involved during the year after the notice is given.
(c) If in a given area of responsibility RDOEC did not satisfy the performance requirement set forth in section 4.a(3)(a) above for any of the 12-month periods ending May, June, or July 1996, a failure by RDOEC to satisfy that performance requirement in such area of responsibility for any rolling 12-month period ending July 1999 or earlier will not be counted for the purpose of JDIEC's right of termination under section 4.a(3)(b) above. Should RDOEC acquire a dealership which, for any of the 12-month periods ending with the month of acquisition or with one of the two months immediately preceding the month of acquisition, did not satisfy the performance requirement set forth in section 4.a(3)(a) above, a failure by RDOEC to satisfy that performance requirement, in the area of responsibility previously assigned to such acquired dealership, for any rolling 12-month period ending within the first three years of RDOEC's operations there will not be counted for the purpose of JDIEC's right of termination under section 4.a(3)(b) above.
Absorption. The two relevant parameters for oral absorption are the absorption rate constant (ka), describing the rate of absorption, and bioavailability (F), describing the extent of absorption. The ka of the suspension was reported to be different in different patient groups and mostly ranged from 0.40 to 0.77 h-1, which corresponds to an absorption half-life (t1/2) between 0.90 and 1.7 h [35-37]. Both a slower absorption (absorption t1/2 of 17.5 h) as well as a faster absorption (absorption t1/2 of 0.55 h) with a delayed onset of absorption have been reported [38, 39]. High inter-individual variability (53.4%) was reported for the ka upon administration of the posaconazole suspension [39]. For the delayed-release tablet, similar ka values were reported (0.59 h-1 and 0.85 h-1) [40, 41] with inter-individual variability in k (57.5%) being as high as for the oral suspension [41]. Food intake proved to be associated with an increase in ka, but was not expected to have a clinically relevant influence, because it had no impact on bioavailability or steady-state exposure parameters [41]. The mean value for F for the posaconazole suspension and delayed-release tablet were reported to be around 50% in healthy volunteers [42, 43], but was found to be about 2.6 times lower in patients receiving the posaconazole suspension [39]. It has been shown that food intake and nutritional supplements increase the F by improving solubility and delaying gastric emptying, thereby enhancing posaconazole exposure. Higher gastric pH and gastrointestinal motility decrease F of the oral suspension by reducing the solubility and shortening gastric residence time [44- 47]. Additionally, administering the posaconazole suspension via nasogastric tube showed approximately 20% decreases in exposure compared to oral administration in healthy volunteers [47]. In immunocompromised patients, coadministration of proton pump inhibitors (PPI) or metoclopramide, or the occurrence of mucositis or diarrhea were proven to reduce the F of posaconazole by 45%, 35%, 58%, and 45%, respectively, while administration with nutritional supplements could increase F by 129% [39]. The systemic exposure of posaconazole upon dosing of the delayed-release tablet formulation is less susceptible to the aforementioned gastric conditions than the suspension. Coadministration with antacids, PPIs, H2 receptor functional antagonists, or metoclopramide proved to have a non-clinically relevant impact on the F of posaconazole in a hea...
Absorption. The absorption of the treated concrete under total immersion shall not exceed 0.5 percent after 48 hours or 1.5 percent after 50 days per ASTM C 642 as modified below for non-air entrained concrete.
Absorption. After oral administration, binimetinib is rapidly absorbed with a median Tmax of 1.5 hours. Following a single oral dose of 45 mg [14C] binimetinib in healthy subjects, at least 50 % of the binimetinib dose was absorbed. Administration of a single 45 mg dose of binimetinib with a high-fat, high-calorie meal decreased the maximum binimetinib concentration (Cmax) by 17 %, while the area under the concentration-time curve (AUC) was unchanged. A drug interaction study in healthy subjects indicated that the extent of binimetinib exposure is not altered in the presence of a gastric pH-altering agent (rabeprazole).
Absorption. Add the following:
